Dirk Sibbing
Overview
Explore the profile of Dirk Sibbing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
8117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortega-Paz L, Rollini F, Franchi F, Sibbing D, Angiolillo D
Interv Cardiol Clin
. 2024 Dec;
13(4S):e1-e30.
PMID: 39674676
Antiplatelet therapy involving aspirin and a P2Y receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y inhibitors is frequently observed in clinical settings for various reasons,...
2.
Angiolillo D, Galli M, Alexopoulos D, Aradi D, Bhatt D, Bonello L, et al.
JACC Cardiovasc Interv
. 2024 Nov;
17(22):2639-2663.
PMID: 39603778
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is...
3.
Sibbing D, Nicolas J, Spirito A, Vogel B, Cao D, Stipek W, et al.
Clin Cardiol
. 2024 Aug;
47(9):e24326.
PMID: 39206792
Objective: This study aimed to evaluate the comparative effectiveness and safety of clopidogrel versus aspirin as monotherapy following adequate dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS)....
4.
Valgimigli M, Landi A, Angiolillo D, Baber U, Bhatt D, Bonaca M, et al.
Circulation
. 2024 Jul;
150(4):317-335.
PMID: 39038086
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has...
5.
Sibbing D, Massberg S, Rizas K
JACC Cardiovasc Interv
. 2024 Jun;
17(11):1371-1373.
PMID: 38866459
No abstract available.
6.
Aytekin A, Scalamogna M, Coughlan J, Lahu S, Ndrepepa G, Menichelli M, et al.
Clin Res Cardiol
. 2024 May;
113(7):1060-1069.
PMID: 38740722
Background: The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present study sought to investigate the impact of ticagrelor...
7.
Sibbing D, Blaha M, Chawla R, Lavalle-Cobo A, Kishore A, Lanas A, et al.
Eur Cardiol
. 2024 May;
19:e01.
PMID: 38708371
Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy,...
8.
Santilli F, Albrecht G, Blaha M, Lanas A, Li L, Sibbing D
Am J Prev Cardiol
. 2024 May;
18:100675.
PMID: 38694728
Cardiovascular disease (CVD) remains the leading cause of death worldwide. The risk of a cardiovascular (CV) event is not static and increases along a continuum, making identification and management complex....
9.
10.
Rubboli A, Atar D, Sibbing D
Intern Emerg Med
. 2024 Apr;
19(6):1537-1548.
PMID: 38594458
After an acute coronary syndrome (ACS) it is imperative to balance the bleeding vs. the ischemic risk given the similar prognostic impact of the two events. Since the post-discharge bleeding...